These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 17245000)

  • 21. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
    Karnon J; Delea T; Johnston SR; Smith R; Brandman J; Sung J; Goss PE
    Pharmacoeconomics; 2006; 24(3):237-50. PubMed ID: 16519546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and economic benefits of aromatase inhibitor therapy in early-stage breast cancer.
    Glück S; Gorouhi F
    Am J Health Syst Pharm; 2011 Sep; 68(18):1699-706. PubMed ID: 21880884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer.
    Karnon J; Johnston SR; Jones T; Glendenning A
    Ann Oncol; 2003 Nov; 14(11):1629-33. PubMed ID: 14581270
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole.
    Skedgel C; Rayson D; Dewar R; Younis T
    Breast; 2007 Jun; 16(3):252-61. PubMed ID: 17207623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer].
    Gamboa O; Díaz S; Chicaíza L; García M
    Biomedica; 2010; 30(1):46-55. PubMed ID: 20890549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer.
    Younis T; Rayson D; Dewar R; Skedgel C
    Ann Oncol; 2007 Feb; 18(2):293-8. PubMed ID: 17095569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
    Lux MP; Wöckel A; Benedict A; Buchholz S; Kreif N; Harbeck N; Kreienberg R; Kaufmann M; Beckmann MW; Jonat W; Hadji P; Distler W; Raab G; Tesch H; Weyers G; Possinger K; Schneeweiss A
    Onkologie; 2010; 33(4):155-66. PubMed ID: 20389141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer.
    El Ouagari K; Karnon J; Delea T; Talbot W; Brandman J
    Breast Cancer Res Treat; 2007 Jan; 101(1):37-49. PubMed ID: 16821085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer].
    Sasse AD; Sasse EC
    Rev Assoc Med Bras (1992); 2009; 55(5):535-40. PubMed ID: 19918652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance.
    Frederix GW; van Hasselt JG; Schellens JH; Hövels AM; Raaijmakers JA; Huitema AD; Severens JL
    Pharmacoeconomics; 2014 Jan; 32(1):47-61. PubMed ID: 24263964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anastrozole data show continued delay in relapse, but no clear survival advantage.
    Travis K
    J Natl Cancer Inst; 2005 Jan; 97(2):86-7. PubMed ID: 15657334
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
    Skedgel C; Rayson D; Dewar R; Younis T
    Breast Cancer Res Treat; 2007 Mar; 101(3):325-33. PubMed ID: 16897433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letrozole: a review of its use in postmenopausal women with breast cancer.
    Simpson D; Curran MP; Perry CM
    Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
    Piskur P; Sonc M; Cufer T; Borstnar S; Mrhar A
    Anticancer Drugs; 2006 Jul; 17(6):719-24. PubMed ID: 16917219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
    Risebrough NA; Verma S; Trudeau M; Mittmann N
    Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reducing the risk of late recurrence in hormone-responsive breast cancer.
    Cufer T
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii18-25. PubMed ID: 17890210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing the cost of adjuvant anastrozole with the benefits of managing less patients with relapsed breast cancer.
    Thomas RJ; Williams M; Glen J; Callam M
    Breast Cancer Res Treat; 2009 Sep; 117(2):289-95. PubMed ID: 19122976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.